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ABSTRACT 
 
Background: Oral cancer is an important public health problem in Southeast Asian countries. 
Generally, cases are reported in advanced stages, resulting in prolonged treatment, high 
financial burden, and poor prognosis. When diagnosed early, treatment is simple and 
inexpensive.  
 
Materials and Methods: A sequential explanatory study design, cross-sectional survey 
followed by in-depth interviews, will be used to assess various factors contributing to the 
patient and diagnostic intervals in oral cancer. At the outset, Data collection tools will be 
developed and validated. The study protocol is designed as per the “Aarhus statement” for 
early diagnosis research. In-depth interviews with selected stakeholders and review of 
documents related to cancer control will constitute the explanatory component of the study 
design. 
 
Discussion: Primary prevention helps in reducing cancer incidence whereas secondary 
prevention helps in reducing morbidity and mortality. Early diagnosis is a key secondary 
prevention strategy. Research on early diagnosis of cancer in general and oral cancer, in 
particular, is scarce. In this regard, a comprehensive and thorough evaluation of various 
factors facilitates or impede early oral cancer symptom presentation will help in designing 
policies and programs to promote early diagnosis of oral cancer. 
 
Keywords: Early cancer diagnosis, Oral cancer, Patient interval, Diagnostic interval, Aarhus 
Statement 
	  
1.  Background 
Cancer incidence is increasing in the world with a staggering eighteen million new cancer 
cases in 2018. Nearly half of these cases were from Asia (Bray et al., 2018). Low middle-
income countries account for 72% of worlds cancer deaths (Institute of Medicine, 2007). The 
cancer pattern also varies across different world regions. Breast cancer is the most common 
cancer in all six World Health Organization (WHO) regions. If we observe the cancer 
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incidence among men, prostate cancer is the most common cancer in WHO regions of 
Europe, Africa, lung cancer in western pacific and east Mediterranean regions and lip, oral 
cavity cancers in South East Asia region (Bray et al., 2018). Oral cancer is the most common 
type of cancer among men in South Asian Countries like India, Srilanka, Pakistan, and 
Bangladesh and contributes nearly one-fourth of all new cases of cancer (Bray et al., 2018). 
Oral cancer is characterized by marked geographical variations in its incidence and 
prevalence rates (Warnakulasuriya, 2009). Oral cancer is the seventeenth most common 
cancer in the world with a share of 2.2% in total cancer incidence. India presents an entirely 
different scenario where oral cancer ranks second with a 10.4% share of total cancer 
incidence (Bray et al., 2018). WHO predicts a 66% increase in the incidence of oral cancer in 
India by the year 2040, which is higher than the similar estimate for Asia and the world 
(Ferlay J et al., 2018). The observed trends in incidence and mortality among men and 
women are closely correlated with the patterns and trends in tobacco and alcohol use 
(Sankaranarayanan, Ramadas, Amarasinghe, Subramanian, & Johnson, 2015). The five-year 
survival rate of early-stage cancer exceeds 80%, while that of patients with advanced stages 
falls below 20%. Globally, more than half of the oral cancer patients report in late stages 
(Sankaranarayanan et al., 2015; van der Waal, 2013; Warnakulasuriya, 2009). Oral cancer 
has a long preclinical phase that consists of well-documented precancerous lesions 
(Sankaranarayanan et al., 2015). Unlike other cancers, these lesions can be easily recognized 
(Farah et al., 2014). Early identification and proper management of these lesions will ward 
off mortality (Messadi, 2013). Health care providers including dentists can detect these 
precancerous and cancerous lesions through oral visual examination (Sankaranarayanan et al., 
2015). Despite all these favorable circumstances for prevention, most of the time, the lesion 
is reported or diagnosed at an advanced stage (Güneri & Epstein, 2014). Primary prevention 
through control of risk factors and secondary prevention through early detection are the two 
strategies for oral cancer control (World Health Organization, 2017). Early detection has two 
components, namely, screening and early diagnosis. Screening refers to the identification of 
asymptomatic disease in an apparently healthy population. For a disease to be included in a 
screening program, it should pass through a detectable pre-clinical phase and early treatment 
should offer some advantage over late treatment (Isabel dos Santos Silva, 1999). 
No national or international guidelines recommend population-based screening for oral 
cancer except for high-risk population (Brocklehurst et al., 2013; USPSTF, 2013). Early 
diagnosis is the recognition of symptomatic cancer in its early clinical phase (World Health 
Organization, 2007). The purpose here is to identify the disease at the earliest possible 
opportunity (World Health Organization, 2017). Early diagnosis integrated with 
approachable, affordable and efficacious treatment will lead to furtherance in both the stage 
of cancer at presentation and mortality from cancer (World Health Organization, 2017). Thus, 
delay in diagnosis is considered as an impediment for prognosis and survival. Pack and Gallo 
first introduced the concept of delay in 1938 and they defined it as an interval between the 
onset of symptoms and the first visit to a physician. The undue delay was arbitrarily defined 
as three months or more (Pack & Gallo, 1938). The first model to explain the delay in 
seeking cancer diagnosis was given by Andersen (Andersen, Cacioppo, & Roberts, 1995). 
The general model of patient delay proposed by Andersen comprised of a series of stages, 
each characterized by a distinct set of definitions and appraisal processes. The stages include 
Appraisal delay, Illness delay, Behavioral delay, Scheduling delay, and Treatment delay. 
Later, Olesen et al proposed a model with various milestones and time intervals to explain the 
processes leading to diagnosis and treatment of cancer (Olesen, Hansen, & Vedsted, 2009). 
They include Total delay, Patient delay, Doctor delay, System delay, Primary care delay, 
Secondary care delay, Diagnostic delay, and Treatment delay (Olesen et al., 2009). Walter et 
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al refined the Andersen model and proposed the Model pathways to treatment (Walter, 
Webster, Scott, & Emery, 2012). A recent document by the World Health Organization on 
early diagnosis of cancer recommends using the term "interval" instead of "delay" as the later 
amount to blame the patient and provider for the delay (World Health Organization, 2017). 
The document further refines the time points and intervals described in the above models. 
The intervals include patient interval, diagnostic interval, and treatment interval (World 
Health Organization, 2017). The patient interval is the period from the recognition of 
signs/symptoms suggestive of cancer to the day he/she meet a health care provider to discuss 
the same. The diagnostic interval is the period from the date of the first visit to a health care 
provider to discuss a symptom suggestive of cancer to the date of obtaining a definitive 
histopathological diagnosis (Walter et al., 2012; World Health Organization, 2017). 
Treatment interval is the duration from definitive diagnosis to initiation of cancer treatment 
(Walter et al., 2012; World Health Organization, 2017). Several factors including 
demographical, psychological, social, cultural, disease-related, and system-related factors 
affect the length of these intervals (Weller et al., 2012; World Health Organization, 2017). 
A greater understanding of these intervals is essential for planning and implementing 
cancer control policies and programs (Coxon et al., 2018). Unfortunately, most of the studies 
carried out in the field of early diagnosis were marred by methodological incongruities, 
making it difficult for comparisons and interpretations (Andersen, Vedsted, Olesen, Bro, & 
Søndergaard, 2009; Weller et al., 2012). As a result of this, a consensus-working group 
comprising of experts in the field of early diagnosis research had gathered at Aarhus, 
Denmark in 2011 for evaluating existing research and to produce checklists and guidelines to 
guide early diagnosis researchers (Weller et al., 2012). The working group found that there is 
little consistency in the definitions and measurements of key time points and intervals. They 
also concluded that few studies have used a theoretical framework and there is no 
transparency in the use or development of study instruments (Weller et al., 2012). The 
recommendations put forward by the consensus-working group are known as “Aarhus 
Statement”. It provides recommendations for definitions and methodological approaches and 
a checklist for designing early diagnosis research studies (Weller et al., 2012). Studies 
published during the post-Aarhus statement period have also failed to follow Aarhus 
recommendations. Moreover, there are very few validated instruments to measure these 
intervals. The only validated tool (Neal et al., 2014) available for measuring the various 
intervals in the diagnostic journey of cancer did not have provision for measuring those time 
intervals in oral cancer patients. Knowing more about the magnitude of this late presentation 
as well as the contributing factors for longer intervals will help in managing this public health 
problem. The current literature on early diagnosis was largely from western countries. These 
literature focus much on cancers other than oral cavity cancers as the incidence of oral cancer 
is very low in those countries. There are very few studies exist in the literature on early 
diagnosis of oral cancer and within that, the contribution from South East Asia is meager. 
The scarcity of studies from India on early diagnosis of oral cancer necessitates designing a 
study for estimating various time intervals in the diagnostic journey of oral cancer and 
identifying various factors contributing to those intervals in line with the Aarhus statement.  
 
The objectives of the current study are as follows: 
1. Estimate the duration of patient interval in the diagnostic journey of oral cancer patients 
of a tertiary cancer center in northern Kerala. 
2. Estimate the duration of diagnostic interval in the diagnostic journey of oral cancer 
patients of a tertiary cancer center in northern Kerala.  
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3. Study the various factors associated with the patient interval in the diagnostic journey of 
oral cancer patients of a tertiary cancer center in northern Kerala. 
4. Mapping the structure and function of oral cancer control in the state.  
5. To develop and validate instruments for capturing the duration of the patient interval, 
diagnostic interval and various factors contributing to the patient interval in the 
diagnostic journey of oral cancer.  
 
2.  Methods and Analysis 
2.1  Study design 
A sequential explanatory study design will be used for conducting this study. Sequential 
Explanatory Design is characterized by the collection and analysis of quantitative data 
followed by the collection and analysis of qualitative data. Priority is typically given to the 
quantitative data. The purpose of the sequential explanatory design is typically to use 
qualitative results to assist in explaining and interpreting the findings of a primarily 
quantitative study (Creswell, Plano Clark, Gutmann, & Hanson, 2003). This study has three 
phases. 
 
Phase 1: Development and validation of tools for a cross-sectional survey 
Tools will be developed and validated for conducting the cross-sectional survey. The 
outcome of phase 1 will be a newly developed and validated interview schedule for 
measuring patient and diagnostic interval and a questionnaire to identify the various factors 
related to the patient interval.  
 
Steps for developing the tool: 
1. Literature review: A literature review will be conducted to identify the various factors 
contributing to the patient interval. An inventory will be created from the previous 
questionnaires identified in the literature review. 
2. Expert consultation: The inventory will be discussed with experts individually. The 
experts include Head and neck oncologists, Oral medicine specialists, ENT specialist, 
Epidemiologists, Psycho oncologists, Dentists, and General practitioners. These discussions 
will help in identifying factors unaddressed in other studies as well as factors relevant to our 
setting.  
3. Content validity: Content validity will be objectively measured through a content validity 
index (CVI). CVI provides a quantitative measurement of content validity. The experts will 
be provided a copy of the tool individually and will be asked to rate each item based on 
relevance as relevant or irrelevant. The content validity index will be computed as the 
number of experts giving a rating of relevant divided by the total number of experts. The 
items having a CVI score of 0.80 or above only will be retained in the tool.  
4. Back translation: Translation-back translation of the draft tool will be carried out to 
produce a conceptually equivalent version of the tool in the local language.  
5. Face validity: The translated version of the questionnaire will be administered to 10 
people as cognitive piloting. Cognitive piloting is a method for identifying problems with the 
question-wording. Besides the participants' overall assessment of the questionnaire, 
participants will be asked to review each question based on the following checklist:  
a) The meaning, clarity, and purpose of the question  
b) Difficulty in answering the question  
c) Suggestions, if any, to improve the question  
Social Science Protocols, December 2019, 1-17.  
http://dx.doi.org/10.7565/ssp.2019.2670 
	  
	  
5	  
6. Reliability: The main outcome variables of the “patient interval” and “diagnostic interval” 
are time durations obtained from calendar dates. Reliability analysis will not be carried out as 
the instrument intends to collect only factual, objective information. The Protocol for 
calculating ‘pseudo-exact’ dates from estimated dates will be used for calculating the time 
intervals (Neal et al., 2014). 
 
Phase 2: Hospital-based cross-sectional study  
Hospital-based patient interview using the newly developed and validated instrument will 
constitute the second phase of the study. The patient interview will be done within 3 months 
from the date of patient registration at the institution to minimize recall bias. The expected 
outcome of phase 2 study includes the mean duration of the patient interval, mean duration of 
diagnostic interval and identifying various factors affecting patient interval. 
 
Phase 3: In-Depth Interviews and Mapping the structure and function of oral cancer 
control 
In-Depth Interviews: In-Depth Interviews with patients, health care providers, health care 
administrators, community leaders, etc. as per the findings of the cross-sectional survey 
conducted in phase 2 will constitute the explanatory part of this sequential explanatory study. 
Selection of participants, as well as the preparation of the interview guide, will depend on the 
outcome of the cross-sectional survey. In-Depth Interviews will help in explaining the 
findings of the hospital-based cross-sectional survey. The participants for the in-depth 
interview will be selected purposively. The expected outcome is interview guideline and 
findings from an in-depth interview.  
Mapping the structure and function of oral cancer control: Mapping of the structure and 
function of the oral cancer control will be done by reviewing Govt documents, institutional 
documents, and other online resources. The expected outcome is to map existing public 
health facilities and their role for the prevention, early diagnosis, and treatment for oral 
cancer. It will also document the referral pattern and other government initiatives for the 
control of oral cancer.   
 
2.2  Study setting 
A tertiary cancer center in northern Kerala will be the study setting for the cross-sectional 
study. Data on the patient interval, diagnostic interval and factors contributing to these 
intervals will be collected in a direct patient interview using the newly developed and 
validated instrument. The principal investigator will inform each participant about the 
purpose of the research and will obtain signed informed consent from all participants. The 
participants will be interviewed in a room adjacent to the out-Patient Department or ward or 
any other place convenient to the patient ensuring privacy for the data collection. Time points 
like date of biopsy, date of biopsy report, patient registration number, and disease stage 
information will be collected from the patient case files. The secondary data to study the 
structure and function of oral cancer control in the state will be collected from published 
government reports and online government sources. The in-depth interview schedule will be 
prepared after evaluating the findings of the cross-sectional study. Participants, as determined 
after evaluating the outcome of phase 2, will be approached by the principal investigator for 
the interview. They will be interviewed at a place and time convenient to them. 
 
 
 
Social Science Protocols, December 2019, 1-17.  
http://dx.doi.org/10.7565/ssp.2019.2670 
	  
	  
6	  
2.3  Participants and sample size 
The estimated sample size for the cross-sectional survey is 260. The sample size for the in-
depth interview is 15 to 30 participants or until we reach saturation. The sample size was 
estimated by Epi info version 3.01. According to a study done in Uttar Pradesh, India 
(Akram, Siddiqui, & Karimi, 2014), the proportion of oral cancer patients with a patient 
interval of more than 3 months was 60%. Taking 60% as the anticipated prevalence of oral 
cancer patients with a patient interval of more than 3 months, with a 95% confidence interval 
between 54% and 66%, the sample size was estimated as 257 rounded off to 260. The latest 
published hospital-based cancer registry data (2015), from the institution where the study will 
be conducted, reports 450 new oral cancer patients for that year. Hence, we expect 260 new 
oral cancer patients within 7 months. All oral cancer patients reporting at the institution 
during the study period will be invited to participating in the study. All the invited patients 
consenting to participate in the study will be included in the study if they satisfy the inclusion 
criteria/exclusion criteria. The subjects for the in-depth interview will be selected purposively 
based on the findings of the cross-sectional survey conducted in phase 2. We plan to conduct 
10 to 20 interviews or until we reach saturation. The inclusion-exclusion criteria for the study 
are as follows. 
 
Inclusion criteria:  
Newly registered Patients with the following malignant neoplasms will be included in the 
study. They are malignant neoplasm of lip (C00), base of tongue (C01), other and unspecified 
parts of tongue (C02), gum (C03), the floor of mouth (C04), palate (C05), other and 
unspecified parts of the mouth (C06). 
 
Exclusion criteria: 
• Those known to have, or had, other cancers; patients who were on routine surveillance 
for cancer and presence detected via that system. 
• Those who are not consenting to participate. 
• Oral cancer patients who are unable to participate due to health reasons or any other 
reasons.  
• Oral cancer patients with recurrence. 
• Patients who have completed treatment or partially treated for oral cancer from 
elsewhere. 
 
2.4  Variables and data sources 
The dependent variables for the study are the patient interval, diagnostic interval, and oral 
cancer stage at diagnosis. Time points used to calculate these intervals include ‘Date of the 
first symptom', ‘Date of the first presentation' and ‘Date of diagnosis'. Date of the first 
symptom is the date on which a patient identifies a bodily change or symptom in the oral 
cavity. Date of the first presentation is the date on which the patient consults a health care 
provider to discuss the bodily change or symptom in the oral cavity. Definitions of these time 
points are based on the ‘phases of clinical pathway' described by Olesen et al (Olesen et al., 
2009). These time points are subject to recall bias. Thus, the timing of the patient interview is 
a determining factor in the accuracy of these measurements. Scheduling an interview date too 
close to the date of diagnosis may be insensitive and too long will lead to recall bias and 
participant attrition due to death and terminal illness. In this study, the patient interview will 
be done within 3 months from the date of diagnosis. Self-reported information on the date of 
first reporting will be crosschecked with prescription notes, if available. Date of diagnosis 
will be recorded based on the hierarchical rationale developed by the European Network of 
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Cancer Registries: Hierarchy for Defining the Date of Diagnosis. The independent variables 
identified through the preliminary literature review are as follows. 
 
1. Socio-demographic factors:  
Age (Allison, Franco, Black, & Feine, 1998; Gullatte, Hardin, Kinney, Powe, & Mooney, 
2009; Hafström, Johansson, & Ahlberg, 2011; Jassem et al., 2014; Memon, Shaikh, Rizwan, 
& Sardar, 2013; Yu, Murugiah, Khan, & Mehmood, 2015).  
Sex (Abu-Helalah, Alshraideh, Al-Hanaqtah, Da’na, & Mubaidin, 2016; Allison et al., 1998; 
Chandra, Mohan, Guleria, Singh, & Yadav, 2009; Gullatte et al., 2009; Hafström et al., 2011; 
Jassem et al., 2014; Memon et al., 2013; Stuver et al., 2011; Thakur, Humne, & Godale, 
2015; Yu et al., 2015). 
Marital status (Abu-Helalah et al., 2016; Hafström et al., 2011; Jassem et al., 2014; Memon 
et al., 2013; Stuver et al., 2011; Thakur et al., 2015; Yu et al., 2015). 
Residential status (Chandra et al., 2009; Hafström et al., 2011; Jassem et al., 2014; Thakur et 
al., 2015). 
Religion (Hafström et al., 2011). 
Socioeconomic status (Jassem et al., 2014; Marlow, McGregor, Nazroo, & Wardle, 2014). 
Knowledge of tobacco causes cancer (Marlow et al., 2014). 
Education (Gullatte et al., 2009; Memon et al., 2013; Thakur et al., 2015). 
Ethnicity (Jassem et al., 2014; Memon et al., 2013). 
Migration status, distance from health facility and occupation (Hafström et al., 2011; Yu et 
al., 2015). 
 
2. Health behavioral factors:   
Cigarette smoking (Hafström et al., 2011; Memon et al., 2013; Thakur et al., 2015; Yu et al., 
2015). 
Alcohol use (Gullatte et al., 2009; Hafström et al., 2011; Memon et al., 2013; Thakur et al., 
2015; Yu et al., 2015).  
Betel quid use (Hafström et al., 2011).  
Regular medical consultation (Marlow et al., 2014).  
Regular dental consultation (Thakur et al., 2015).  
Consulting for early detection (Marlow et al., 2014).  
 
3. Psychosocial factors:  
Attribution of the symptom as minor (Abu-Helalah et al., 2016). 
Absence of fear (Abu-Helalah et al., 2016). 
Use of alternate therapy (Abu-Helalah et al., 2016). 
Negative thoughts on cancer (Marlow et al., 2014). 
Perceptions of being under stress in the period before diagnosis (Jassem et al., 2014). 
Severity of life events in the patient delay period (Memon et al., 2013). 
Perceived ability to seek help for oral symptoms (Memon et al., 2013).  
 
4. Disease factors:  
Dental status (Stuver et al., 2011; Yu et al., 2015).  
Tumor site (Hafström et al., 2011; Stuver et al., 2011).  
Tumor size (Hafström et al., 2011; Stuver et al., 2011).  
Comorbid conditions (Chandra et al., 2009).  
TNM stage (Hafström et al., 2011).  
Lymph node metastasis (Hafström et al., 2011).  
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Initial sign or symptom (Hafström et al., 2011; Jassem et al., 2014).  
Medical history (Jassem et al., 2014).  
Dental history (Jassem et al., 2014).  
Experience of symptoms (Thakur et al., 2015).  
Initial self-diagnosis (Thakur et al., 2015).  
 
The list of independent variables will be finalized during instrument development.  
Data on the patient interval, diagnostic interval and factors contributing to these intervals will 
be collected in a direct patient interview using the newly developed and validated 
instruments. Neal et al guideline will be followed for calculating the pseudo exact date from 
the estimated date provided by the patient (Neal et al., 2014). Time points like date of biopsy, 
date of biopsy report, patient registration number, and disease stage information will be 
collected from the patient case files. The secondary data to study the structure and function of 
oral cancer control in the state will be collected from published government reports and 
online government sources. The in-depth interview schedule will be prepared after evaluating 
the findings of the cross-sectional study. Participants for the In-Depth Interview will be 
identified after evaluating the outcome of phase 2. They will be informed about the purpose 
of the study and the principal investigator will obtain the consent of those willing to take part. 
They will be interviewed at a place and time convenient to them. 
 
2.5  Bias 
As study requires recollection of past incidences, there is a possibility for recall bias. For 
reducing recall bias in this study, we will conduct the patient interview within 3 months from 
the date of diagnosis. 
 
2.5  Limitations 
The study participants will be selected from a single institution. This will have 
implications on the generalizability of results. However, the study setting is the only 
comprehensive cancer care center in the region and it provides subsidized treatment as per 
government norms. The early diagnosis research studies were conducted either in hospitals or 
from cancer registry data. The registry system in our place is in a developmental phase and 
they cover a less geographical area in comparison to the hospital's catchment area. 
 
2.6  Plan for data analysis 
Descriptive statistical methods will be used (frequencies, percentages, means, standard 
deviations depending on whether the variables are categorical or continuous). Binary logistic 
and multiple linear regression models will be constructed to identify significant predictors. 
Early (stage 1 and 2) vs. late (stage 3 and 4) stages of oral cancer will be further explored for 
differences in duration and factors related to the patient and diagnostic interval. Data will be 
analyzed to understand gender and class differentials. Thematic analysis will be used for 
qualitative data. Thematic analysis will be used for qualitative data. Cancer-related 
documents will be reviewed using a checklist.  
 
2.7  Ethical consideration 
The principal investigator (PI) has obtained approval from the Institutional Ethics 
Committee for conducting the study. The discomforts expected from the study are minimal. 
Participants have to spend 20-30 minutes for the data collection and they may have difficulty 
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in recollecting information related to their symptoms. Some of the cancer patients during the 
initial days of diagnosis may find it difficult to accept it. The study participants will be 
approached during the physician-waiting period, which is normally, extends to 30 min to 1hr. 
Thus, the patient will not have to spend extra time on the study. The instrument will have a 
checklist of all possible symptoms and a calendar that will help the patient to identify the past 
events. The timing of the data collection will be scheduled in such a way that it will not be 
too close to the date of diagnosis as the majority of the patients will find it difficult to accept 
the reality initially. The institution has a dedicated psycho-oncology department that provides 
psychological support to all newly diagnosed cancer patients. Data collection will be 
scheduled on a follow-up visit as convenient to them. No invasive procedures are involved in 
the study and therefore no adverse events are expected. PI will be responsible for safekeeping 
the data, privacy, and confidentiality of the subjects will be ensured at all levels. The PI 
before the data collection will obtain an informed signed consent from the participants, after 
briefing on the study objectives, purpose, benefit, risks and voluntariness to decide 
participation. The participant will be provided time (not less than 15 minutes) to read and 
understand the consent form. Ethical approval has been obtained from two Institutional ethics 
committees (1617/IRB-IEC/13/MCC/13-05-2019/5 and SCT/IEC/1388/JUNE-2019). 
 
3.  Discussion 
The starting point of any discussion on the patient and the diagnostic interval is the quest 
for an acceptable duration. From the early study of Pack and Gallo (Pack & Gallo, 1938) to 
the present day studies (Abu-Helalah et al., 2016; Akram et al., 2014; Chandra et al., 2009; 
Ibrahim & Oludara, 2012; Mohd Mujar et al., 2017), three months is generally considered as 
an acceptable patient interval (Andersen et al., 2009; Thakur et al., 2015). Similarly, one 
month is considered an acceptable diagnostic interval (Abu-Helalah et al., 2016; Morelatto, 
Herrera, Fernández, Corball, & López de Blanc, 2007). There are other studies, which 
consider a shorter period for patient interval and a longer period for diagnostic interval as an 
acceptable period (Allison et al., 1998; Lim et al., 2014; Olesen et al., 2009). Multifarious 
study designs and summary measures were used for conducting the study and to report the 
findings in early diagnosis research. Although cross-sectional study design is the preferred 
one (Abu-Helalah et al., 2016; Bourdeanu et al., 2013; Garcia et al., 2012; Gullatte et al., 
2009; Hafström et al., 2011; Ibrahim & Oludara, 2012; Jassem et al., 2014; Memon et al., 
2013; Mohd Mujar et al., 2017; Yu et al., 2015), cohort (Stuver et al., 2011; Thakur et al., 
2015) and qualitative designs (Marlow et al., 2014) were also used. Very few studies reported 
measures of dispersion to describe study findings. These observations confirm with expert 
review findings that lead to the preparation of Aarhus Statement (Andersen et al., 2009; 
Weller et al., 2012). An oral cancer-specific review of early diagnosis research also reported 
similar observations (Varela-Centelles et al., 2018). The mean patient interval duration 
reported from various countries (Kerdpon, Jantharapattana, & Sriplung, 2018) vary 
considerably necessitating the need for a region-specific estimate of these durations to assess 
the need and status of early cancer control initiatives.    
Several factors influence the patient interval duration. Factors found to be significant in 
one study may appear as an insignificant one in another study. This poses the biggest 
challenge to the current research. Studies addressing factors related to this interval were 
generally focused on socio-demographic factors even though few have attempted to study the 
psychosocial, health behavioral and equity-related factors. Even though socio-demographic 
factors are the most frequently studied ones, it is too difficult to generalize the findings from 
these studies, as contradictory observations exist in the literature. Old age is a risk factor for 
Social Science Protocols, December 2019, 1-17.  
http://dx.doi.org/10.7565/ssp.2019.2670 
	  
	  
10	  
oral cancer (Ram et al., 2011) hence researchers also want to know its relationship with 
patient interval. Out of the eight studies evaluated its significance, only two (Akram et al., 
2014; Panzarella et al., 2014) could demonstrate such a relationship. The majority found no 
such relations(Alahapperuma & Fernando, 2017; Guggenheimer, Verbin, Johnson, 
Horkowitz, & Myers, 1989; Kerdpon & Sriplung, 2001; Llewellyn, Johnson, & 
Warnakulasuriya, 2004; Onizawa et al., 2003; Scott, McGurk, & Grunfeld, 2008). Low 
socioeconomic status is an independent risk factor for developing oral cancer (Conway et al., 
2008) and also for a prolonged patient interval (Akram et al., 2014). A study by Sandeep et al 
from India refutes the presence of such an influence on the patient interval (Sandeep et al., 
2000).  
Similarly, rural residence and levels of education were also examined in various studies 
but the current evidence is insufficient to make any inference. Studies from India, Srilanka, 
and Thailand (Alahapperuma & Fernando, 2017; Baishya et al., 2015; Kerdpon et al., 2018) 
found education as a significant factor in determining patient interval but those from USA, 
England, and Italy cannot establish such links (Guggenheimer et al., 1989; Panzarella et al., 
2014; Scott et al., 2008). The stark reflection from this observation is the relevance of 
education in facilitating health care utilization in developing countries. Gender was also 
assessed for any possible association but none of the studies showed it as significant (Akram 
et al., 2014; Alahapperuma & Fernando, 2017; Baishya et al., 2015; Guggenheimer et al., 
1989; Jovanovic, Kostense, Schulten, Snow, & van der Waal, 1992; Kerdpon & Sriplung, 
2001; Llewellyn et al., 2004; Onizawa et al., 2003; Panzarella et al., 2014; Scott et al., 2008). 
A study based on the data from the Clinical Practice Research Datalink (CPRD) in the UK 
found gender delays diagnostic interval in some cancers including head and neck cancer (Din 
et al., 2015). Social support and social networks were minimally (Abu-Helalah et al., 2016; 
Brocklehurst et al., 2013; Gullatte et al., 2009; Morelatto et al., 2007) investigated in the 
reviewed studies. Marital status (Akram et al., 2014; Kerdpon & Sriplung, 2001; Panzarella 
et al., 2014; Scott et al., 2008), number of family members living in the same house (Onizawa 
et al., 2003), escorted by someone(Sandeep et al., 2000), disclosure to others (Akram et al., 
2014) were the few variables that can be related to social support and network but none of 
them were associated with patient interval as per the study findings. Interestingly, a different 
study has found partner support and other support as significant factors for shortening patient 
interval in females (Pedersen, Olesen, Hansen, Zachariae, & Vedsted, 2011). The full 
spectrum of health behaviors was not investigated in any of these studies. Smoking, alcohol 
use, the regularity of visiting a dental or medical provider and use of domestic remedies were 
assessed but could not find any association (Hollows, McAndrew, & Perini, 2000; Onizawa 
et al., 2003; Panzarella et al., 2014; Sandeep et al., 2000). The lower amount of tobacco 
smoked is related to the increased patient interval (Llewellyn et al., 2004) as that might lead 
to underestimation of risk from smoking. Tumor factors, dental factors or comorbid 
conditions were also found to be insignificant (Jovanovic et al., 1992; Llewellyn et al., 2004; 
Sandeep et al., 2000). One study from Srilanka identified the impact of travel cost to a health 
facility as significant(Alahapperuma & Fernando, 2017). 
Research in early oral cancer diagnosis done so far has failed to answer the few questions 
routinely revolve around patient interval duration. The socio-demographic, health-related, 
cognitive and psychological variables affecting the patient interval were either understudied 
or when evaluated, had given contradictory results. The methodologies or definitions used in 
these studies lacked uniformity and hence comparisons were not possible. In these 
circumstances, we have designed our study in conformity with the "Aarhus statement " which 
guides the early cancer diagnosis research (Weller et al., 2012) (Table 1). An exhaustive 
exploration of various factors affecting the reporting of cancer signs and symptoms to a 
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health care provider is necessary for developing policy measures to contain this public health 
challenge.  
 
Table 1.  Protocol consistency with ‘The Aarhus checklist’ for early cancer diagnosis 
research.  
 
No  Item Yes /No 
Definitions Of Time Points And Intervals 
1 For studies requiring the measurement of an interval, are 
the beginning and endpoints of this interval clearly 
defined? 
Yes. Time points 
used are the date of 
the first symptom, 
date of first 
presentation and 
date of diagnosis. 
2 For all time points and intervals described, are there 
precise, transparent and repeatable definitions, and is the 
complexity of time points such as the date of first 
symptom and date of the first presentation addressed? 
Yes  
For studies that require an estimate of the date of the first symptom 
3 Do the researchers refer to a theoretical framework 
underpinning definition of this time point? 
Yes. Phases of the 
clinical pathway by 
Olesen et al 
4 Is there a discussion of the different biases influencing the 
measurement of this time point? 
Yes  
For studies that require measurement of a date of the first presentation to healthcare 
5 Do the researchers discuss the complexity of the date of 
the first presentation? 
Yes  
For studies that require measurement of date of referral 
6 Do the researchers discuss the nature of the referral and 
provide adequate detail – for example, whether it was for 
investigation or consultation by a colleague in secondary 
care? 
NA 
For studies that require measurement of the date of diagnosis 
7 Do the researchers use an existing hierarchical rationale 
for the date of diagnosis measurement? 
Yes. European 
Network of Cancer 
Registries: 
Hierarchy for 
Defining the Date 
of Diagnosis 
Measurement 
8 Is the healthcare context in which the study is based fully 
described? 
Yes  
9 Do the questions on time points and/or intervals clearly 
derive from stated definitions? 
Questions will be 
developed as per 
stated definitions  
10 Do researchers acknowledge the need for theoretical 
validation and refer to the theoretical framework(s) 
underpinning measurement and analysis of the time 
Yes  
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points? 
For studies using questionnaires and/or interviews with patients and/or health-care 
providers 
11 Has a validated instrument been used? A new Instrument 
will be developed 
and validated for 
the study 
12 Have the researchers included a copy of their instrument? The developed 
instrument will be 
published in 
scientific journals 
13 Is there some discussion of how reliability and validity 
(trustworthiness) has been established? 
It is described in the 
steps for tool 
development  
14 Do researchers acknowledge the need for theoretical 
validation and refer to the theoretical framework(s) 
underpinning measurement and analysis of the time 
points? 
Yes  
15 Is there discussion of the different biases influencing 
measurement of the time points, such as how and when 
the question is asked and who is being asked? 
Yes  
16 Is the timing of the interview about the date of diagnosis 
provided? 
Yes  
17 Is there any triangulation of self-reported data with other 
data sources such as case notes? 
Yes  
18 Is data analysis described in full including how and why 
data are categorized, how missing and incomplete data 
are managed, and how outliers at both ends of the 
spectrum are accounted for? 
Not applicable as 
protocol paper  
For studies using primary case-note audit and database analysis 
19 Case-note analysis: is there a clear and precise description 
of how case-note data were used to ascertain time points 
with an acknowledgment of limitations of such data? 
Not applicable  
20  For database analysis: is there a thorough description of 
the database chosen including sampling coverage and 
completeness of information? 
Not applicable  
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